Document:

Exhibit 10.18

 

AMENDING AGREEMENT

 

This Agreement is signed October 12, 2005 but is deemed to confirm the
parties intentions effective as of the 23rd day of November, 2002
(the “Effective Date”).

 

Between:

 

THE UNIVERSITY OF BRITISH COLUMBIA,
a corporation continued under the University Act
of British Columbia and having its administrative offices at 2075 Wesbrook
Mall, Vancouver, British Columbia, V6T 1W5

 

(the “University”)

 

- and -

 

ONCOGENEX TECHNOLOGIES INC.
a corporation incorporated under the laws of Canada, and having offices at
Suite 400, 1001 West Broadway, Vancouver, British Columbia, V6H 4B1

 

(the “Licensee”)

 

WHEREAS:

 

A.            The University and the Licensee entered
into a license agreement with a Commencement Date of November 1, 2001 (“BP5 License Agreement”) pursuant to which
the University granted the Licensee an exclusive worldwide license to the
insulin growth factor binding protein – 5 (“BP5”);
and

 

B.            The University and the Licensee entered
into a license agreement with a Commencement Date of September 1, 2002 (“Bi-Specific License Agreement”) pursuant to
which the University granted the Licensee an exclusive worldwide license to
three separate technologies: (a) insulin growth factor binding protein – 2; (b)
insulin growth factor binding protein – 2 and insulin growth factor binding
protein – 5; and (c) Relaxin;

 

C.            The Parties agreed pursuant to Article 11.4
of the Bi-Specific License Agreement that efforts to develop and exploit a
Product incorporating all or part of the technology or Improvements related to
[***] will be considered development and exploitation of all [***] technologies
for the purpose of Article 11.4 of [***] and the [***] respectively, provided
that the Licensee continues to undertake an active research program with
respect to the technologies which are not the Licensee’s lead Product and the
Licensee continues to pay all patent costs incurred by the University pursuant
to Article 7.1. As also provided under Article 11.4, in the event that Licensee
does not engage in an active research program to the reasonable satisfaction of
the University for each of BP2, Bi-Specific or BP5 for in excess of 24 months,
the Licensee shall either amend the license to exclude the technology or enter
into another agreement with the University to make annual payments to maintain
the license. Further, the Parties agreed in Section 11.4 of 

 

*Certain information in this exhibit has been omitted as confidential,
as indicated by [***]. This information has been filed separately with the
Commission.

 

 

the Bi-Specific License Agreement to amend the BP5 License such that
this intent is consistent between the two Agreements.

 

D.            Pursuant to Section 11.4 of the Bi-Specific
License Agreement, the University and the Licensee now wish to amend the BP5
License Agreement in order that the intent of Section 11.4 of the Bi-Specific
License Agreement be carried out.

 

Now therefore, in consideration of the mutual promises and covenants
contained in this Amending Agreement, the parties hereto covenant and agree
with each other as follows:

 

1.             The first paragraph of
Article 11.4 of the BP-5 License Agreement (but not subparagraphs 11.4(a), (b),
(c) or (d)) is amended by deleting such first paragraph in its entirety and
replacing it with the following:

 

“The Parties acknowledge
that in addition to the insulin growth factor binding protein – 5 (“BP5”) licensed to the Licensee under
this Agreement, the Licensee and the University have entered into a further
license agreement for three separate technologies (the “Bi-Specific License Agreement”): (a) insulin growth factor binding
protein – 2 (“BP2”); (b) insulin
growth factor binding protein – 2 and insulin growth factor binding protein – 5
(“Bi-Specific”); and (c) Relaxin
(“Relaxin”). It is intended that
one of [***] shall become a lead Product of the Licensee, and that the [***]
technologies will be used to support the intellectual property position of the
Licensee in respect of such Product. Further, the Parties acknowledge and agree
that any efforts to develop and exploit a Product incorporating all or part of
the technology or Improvements related to [***] will be considered development
and exploitation of all [***] 
technologies for the purposes of this Article 11.4 and Article 11.4 of
the Bi-Specific License Agreement, provided that the Licensee continues to
undertake an active research program with respect to the technologies which are
not the Licensee’s lead Product and the Licensee continues to pay all patent
costs incurred by the University pursuant to Article 7.1. Therefore, the
Licensee shall use reasonable commercial efforts to develop and exploit the
Technology and any Improvements and to promote, market and sell the Products
and utilize the Technology and any Improvements and to meet or cause to be met
the market demand for the Products and the utilization of the Technology and
any Improvements.

 

Notwithstanding the foregoing, in
the event that the Licensee has not taken reasonable commercial efforts to
develop and exploit each of [***], as evidenced by failing
to engage in an active research program to the reasonable satisfaction of the
University
with respect to each of [***] for in excess of 24 months, the Licensee shall
either amend the license to exclude that technology or
enter into an agreement with the University to make annual payments of [***]
to the University to maintain the 

 

2

 

license for such technology,
notwithstanding the Licensee may not be taking reasonable commercial efforts to
exploit such technology.

 

Without limiting
the generality of the foregoing, the Licensee shall:”.

 

2.             Schedule “A” of the BP5 License Agreement is amended by deleting it in
its entirety and replacing it with the new Schedule “A” attached hereto.

 

3.             Except as modified herein, the University
and the Licensee confirm that the BP5 License Agreement remains unmodified and
in full force and effect.

 

IN WITNESS WHEREOF the parties have executed this Amendment on June             ,
2005, with the intent of confirming the parties intentions as of the Effective
Date.

 

SIGNED FOR AND ON BEHALF OF

THE UNIVERSITY OF BRITISH COLUMBIA

by its duly authorized officers:

 

	
   

  	
  J.P. Heale, PhD, MBA 

  
	
   

  	
  Associate Director 

  
	
   /s/ J.P. Heale 

  	
   

  	
  University-Industry Liaison Office

  
	
  Authorized Signatory

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Authorized Signatory

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  SIGNED FOR AND ON BEHALF OF

  	
   

  
	
  ONCOGENEX TECHNOLOGIES INC.

  	
   

  
	
  By its duly authorized officers:

  	
   

  
	
   

  	
   

  
	
  /s/ Scott Cormack

  	
   

  	
   

  
	
  Authorized Signatory

  	
   

  
				

 

3

 

SCHEDULE “A”

 

DESCRIPTION OF “TECHNOLOGY”

 

The following represents the intellectual property and know-how that is
to be licensed to the Licensee for development of novel treatments of cancer as
contemplated under this License Agreement:

 

	
  UBC 

  File #

  	
   

  	
  Inventor(s)

  	
   

  	
  Title

  	
   

  	
  Serial #

  	
   

  	
  Issued Patent
  #

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  	
   

  	
  [***]

  

 

2.             And all applications that may be filed
based on the foregoing, including, without limitation, all regular, divisional
or continuation, in whole or in part, applications based on the foregoing, and
all applications corresponding to the foregoing filed in countries other than
the United States; and

 

3.             Any and all issued and unexpired
re-issues, re-examinations, renewals or extensions that may be based on any of
the patents described above.

 

4Exhibit 10.20

 

SECOND AMENDING AGREEMENT

 

This Agreement is made as of August 30, 2006 (the “Effective Date”).

 

Between:

 

THE UNIVERSITY OF BRITISH COLUMBIA,
a corporation continued under the University Act
of British Columbia and having its Industry Liaison offices at #103 – 6190
Agronomy Road, Vancouver, British Columbia, V6T 1Z3

 

(the “University”)

 

- and -

 

ONCOGENEX TECHNOLOGIES INC.
a corporation incorporated under the laws of Canada, and having offices at
Suite 400, 1001 West Broadway, Vancouver, British Columbia, V6H 4B1

 

(the “Licensee”)

 

WHEREAS:

 

A.                                   The University and
the Licensee entered into a license agreement with a Commencement Date of
September 1, 2002 with respect to BP-2 and BP-5 (the “Original Bi-Specific License Agreement”)
pursuant to which the University granted the Licensee an exclusive worldwide
license to the Technology, as defined in the Original Bi-Specific License
Agreement;

 

B.                                     The University and
the Licensee entered into a letter agreement dated November 14, 2002 relating
to the Original BP-5 License Agreement (the “Letter
Agreement”);

 

C.                                     The University and
the Licensee entered into an amending agreement effective as of September 12,
2002 with respect to the Original Bi-Specific License Agreement (the “Amending Agreement”);

 

D.                                    The University and
the Licensee now wish to further amend the Original Bi-Specific License
Agreement as set out below (the “Original Bi-Specific License Agreement as
amended by the Amending Agreement and the Letter Agreement is hereafter
referred to as the “Bi-Specific License
Agreement”).

 

Now therefore, in consideration of the premises and the mutual
covenants contained in this Amending Agreement, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties hereto covenant and agree with each other as follows:

 

1.                                       Article
6.6 is hereby amended by adding the following to the end of it:

 

“The University consents to the termination of any shareholders
agreements to which the University and the Licensee may be party, upon the
Licensee becoming a reporting issuer under the Securities Act of British
Columbia.”

 

2.                                       Article
7.1 is hereby deleted and the following substituted therefore:

 

*Certain information in this exhibit has been omitted as confidential,
as indicated by [***]. This information has been filed separately with the
Commission.

 

 

 

“7.1                           The
Licensee shall have the right to identify any process, use or products arising
out of the Technology and any University Improvements that may be patentable and
may seek patent protection with respect thereto, in which case the Licensee
shall take all reasonable steps to apply for a patent in the name of the
University provided that the Licensee pays all costs of applying for,
registering and maintaining the patent in those jurisdictions in which the
Licensee might designate that a patent is required. The choice of patent
counsel will be mutually agreed upon between the University and the Licensee. The
University shall remain the client of such patent counsel, however, the
Licensee will provide direct instructions to the patent counsel on all patent
matters relating to the Technology including filing, prosecution, management,
maintenance, including renewals and term extensions thereof, and the scope and
content of patent applications and to request countries for foreign filings. The
Licensee will pay patent counsel for all costs incurred with respect to any and
all patents relating to the Technology. The Licensee will supply or instruct
the patent counsel to supply the University with copies of all documents and
correspondence received and filed in connection with the prosecution of patents.
The Licensee will keep the University advised as to all material developments
with respect to such applications with
sufficient time for the University to review and respond, and generally not
less than 30 days prior to an applicable patent deadline, unless circumstances
reasonably require the Licensee to act sooner to protect the patents, in which
case the Licensee may act sooner.  
The University shall, as required and at the Licensee’s cost for the
University’s reasonable out-of-pocket expenses, reasonably cooperate with the
Licensee, its lawyers and agents in the filing, prosecution, management and
maintenance of the patents.”.

 

3.                                       The
following is added as Article 10.8:

 

“10.8                     Notwithstanding
anything contained in this Article, the parties acknowledge and agree that the
Licensee may disclose Confidential Information to the extent that may be
required by applicable securities laws in connection with the public offering
of the Licensee’s securities and thereafter to comply with its disclosure
obligations as a public company. If required to make such disclosure by any
applicable securities laws, the Licensee shall inform the University in writing
by giving notice and will consider any reasonable comments the University may
have. Such notice shall be generally not less than 48 hours prior to public
disclosure unless a delay of 48 hours would violate applicable securities laws,
in which case notice shall be as soon as practicable.”

 

4.                                       Article
11.1 is hereby deleted and the following substituted therefore:

 

“11.1                     Notwithstanding
Article 10.7, the Licensee shall not use any of the UBC Trade-marks or make
reference to the University or its name in any advertising or publicity
whatsoever, without the prior written consent of the University, except as
required by law. If the Licensee is required by law to act in contravention of
this Article, the Licensee shall provide the University with sufficient advance
notice in writing to permit the University to bring an application or other
proceeding to contest the requirement.”.

 

5.                                       Article
11.2 is hereby deleted.

 

6.                                       Article
11.4 is hereby deleted and the following substituted therefore:

 

“11.4                     The
parties acknowledge that two separate technologies are included in the
Technology licensed hereunder: (a) insulin growth factor binding protein -2 (“BP2”) and (b) insulin growth factor binding protein – 2 and
insulin growth factor binding protein -5 (“Bi-Specific”).
All such technologies are at a very early stage of development, and it is too
early to determine which invention will become a Product or Products hereunder.
It

 

2

 

is further acknowledged that the Licensee has an existing license
agreement with the University for a technology know as insulin growth factor
binding protein -5 (“BP5”) the (“BP5 License”), and that it is intended that [***] shall
become a lead Product of the Licensee, and that the [***] technologies will be
used to support the intellectual property position of the Licensee in respect
of such Product. Further, the parties acknowledge and agree that any efforts to
develop and exploit a Product incorporating all or part of the technology or
Improvements related to [***] will be considered development and exploitation
of all [***] technologies for the purposes of this Article 11.4 and Article
11.4 of the BP5 License, provided that the Licensee continues to undertake an
active research program with respect to the technologies which are not the
Licensee’s lead Product and the Licensee continues to pay all patent costs
incurred by the University pursuant to Article 7.1. Therefore, the Licensee
shall use reasonable commercial efforts to develop and exploit all or part of
the Technology and any Improvements and to promote, market and sell the
Products and utilize all or part of the Technology and any Improvements and to
meet or cause to be met the market demand for the Products and the utilization
of all or part of the Technology and any Improvements.

 

Notwithstanding the foregoing, in the event that the Licensee has not
taken reasonable commercial efforts to develop and exploit each of [***], as
evidenced by failing to engage in an active research program to the reasonable
satisfaction of the University with respect to each of [***] for in excess of
24 months, the Licensee shall either:

 

(a)                                  amend
the license to exclude that technology; or

 

(b)                                 enter into an
agreement with the University to make annual payments of [***] to the
University to maintain the license for such technology, notwithstanding the
Licensee may not be taking reasonable commercial efforts to exploit such
technology.”.

 

7.                                       The
contact information for delivery of notices in Article 16.0 is amended as
follows:

 

	
  If to the University:

  	
   

  	
  The Managing Director

  
	
   

  	
   

  	
  University – Industry Liaison Office

  
	
   

  	
   

  	
  University of British Columbia

  
	
   

  	
   

  	
  #103 - 6190 Agronomy Road

  
	
   

  	
   

  	
  Vancouver, British Columbia

  
	
   

  	
   

  	
  V6T 1Z3

  
	
   

  	
   

  	
  Telephone:

  	
  (604) 822-8580

  
	
   

  	
   

  	
  Fax:

  	
  (604) 822-8589

  
	
   

  	
   

  	
   

  
	
  If to the Licensee:

  	
   

  	
  The President

  
	
   

  	
   

  	
  OncoGenex Technologies Inc.

  
	
   

  	
   

  	
  1001 West Broadway, Suite 400

  
	
   

  	
   

  	
  Vancouver, British Columbia

  
	
   

  	
   

  	
  V6H 4B1

  
	
   

  	
   

  	
  Telephone:

  	
  (604) 736-3678

  
	
   

  	
   

  	
  Fax:

  	
  (604) 736-3687

  

 

 

8.                                       Article
18.3 is hereby amended by adding the following to the end of it as a separate
paragraph:

 

“Notwithstanding anything contained in this Article 18, the failure to
obtain the prior written consent of the University to the events described in
any of Articles 18.3(d), (e) or

 

3

 

(f) shall not entitle the University to terminate this Agreement if at
the time of such event the Licensee is a public company.”

 

9.                                       In
Article 18.7, the first reference to Article 18.6 is changed to Article 18.5.

 

10.                                 Except
as modified herein, the University and the Licensee confirm that the
Bi-Specific License Agreement remains unmodified and in full force and effect.

 

11.                                 The
Bi-Specific License Agreement as modified by this Agreement constitutes the
entire agreement between the parties relating to the subject matter hereof.

 

This Agreement may be executed by the parties in separate counterparts
and by facsimile, each of which such counterparts when so executed and
delivered shall be deemed to constitute one and the same instrument.

 

IN WITNESS WHEREOF the parties have executed
this Agreement as of the date first above written.

 

SIGNED FOR AND ON BEHALF OF

THE UNIVERSITY OF BRITISH COLUMBIA

by its duly authorized officers:

 

	
   

  	
   

  	
  J.P. Heale, PhD, MBA

  
	
   

  	
   

  	
  Associate Director

  
	
  /s/ J.P. Heale

  	
   

  	
  University-Industry Liaison Office

  
	
  Authorized Signatory

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Authorized Signatory

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  SIGNED FOR AND ON BEHALF OF

  	
   

  	
   

  
	
  ONCOGENEX TECHNOLOGIES INC.

  	
   

  	
   

  
	
  By its duly authorized officer:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  /s/ Scott Cormack

  	
   

  	
   

  
	
  Authorized Signatory

  	
   

  	
   

  

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]